Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02507687 · ClinicalTrials.gov registry record · Phase 3
Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 240
- Enrollment target
NCT02507687 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 240 participants.
The verdict
NCT02507687, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 240 participants
- Enrollment target
Study Summary
This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than medication efficacy (e.g., due to intolerance or nonadherence).
Interventions
- DRUG Bimatoprost SR
- DRUG Sham Bimatoprost SR
- PROCEDURE Selective Laser Trabeculoplasty
- PROCEDURE Sham Selective Laser Trabeculoplasty
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2015-08-27 |
| Est. Completion | 2023-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02507687
The ClinicalTrials.gov registry entry for NCT02507687 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 240 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bimatoprost SR is the first listed.
NCT02507687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02507687 about?
NCT02507687 is a clinical study titled "Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension". This study will evaluate the intraocular pressure (IOP)-lowering effect and safety of bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication for reasons other than me...
What is the current status of trial NCT02507687?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 240 participants. The study started on 2015-08-27. Estimated completion is 2023-05-31.
What interventions are being tested in trial NCT02507687?
The interventions under investigation include: Bimatoprost SR (DRUG), Sham Bimatoprost SR (DRUG), Selective Laser Trabeculoplasty (PROCEDURE), Sham Selective Laser Trabeculoplasty (PROCEDURE).
Who is sponsoring clinical trial NCT02507687?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.